Prevalence of the Pro12Ala missense mutation in the PPARG2 gene in Kuwaiti patients with primary knee osteoarthritis

Annals of Saudi Medicine

Volumn 31, Issue 1, 2011, Pages 35-39

  Al Jarallah, Khaled F ^a   Shehab, Diaa K ^a   Haider, Mohammad Z ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE DETECTION; HUMAN; KNEE OSTEOARTHRITIS; KUWAIT; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; ONSET AGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TEACHING HOSPITAL;

AGED; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HUMANS; KUWAIT; MALE; MIDDLE AGED; MUTATION, MISSENSE; OSTEOARTHRITIS, KNEE; PPAR GAMMA; PROSPECTIVE STUDIES;

EID: 79251644625     PISSN: 02564947     EISSN: 09754466     Source Type: Journal    
DOI: 10.4103/0256-4947.75776     Document Type: Article

References (19)

1. Spectpr TD, MacGregor AJ. Risk factors for osteoarthritis: Genetics. Osteoarthr Cartil 2004;12: S39-44.
2. Shehab DK, Al-Jarallah KF, Al-Awadhi AM, Al-Herz A, Nahar I, Haider MZ. Prevalence of angiotensin-converting enzyme gene insertion-deletion polymorphism in patients with primary knee osteoarthritis. Clin Exp Rheumtol 2008;26:305-10.
3. Loughlin J. Genomic studies and linkage in primary osteoarthritis. Rheum Dis Clin North Am 2002;28:95-109.
4. Fahmi H, Pelletier J P, Martel-Pelletier J. PPAR-gamma ligands as modulators of inflammatory and catabolic responses on arthritis. An overview. J Rheumatol 2002;29:3-14.
5. Fahmi H, Di Battista JA, Pelletier J P, Mineau F, Ranger P, Martel-Pelletier J. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1 beta-induced nitric oxide and matrix metalloproteinase 13 production in human chrondrocytes. Arthritis Rheum 2001;44:595-607.
6. Cheng S, Afif H, Martel-Pelletier J, Pelletier J P, Li X, Farrajota K, et al. Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1 beta-induced membraneassociated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1. J Biol Chem 2004;279:22057-65.
7. Cheng S, Afif H, Martel-Peppetier J, Benderdour M, Pelletier J P, Hilal G, et al. Association of polymorphisms in the peroxisome proliferator-activated receptor g gene and osteoarthritis of the knee. Ann Rheum Dis 2006;65:1394-7.
8. Fahmi H, Pelletier J P, Di Battista JA, Cheung HS, Fernandes J, Martel-Pelletier J. Peroxisome proliferator-activated receptor gmma activators inhibit MMP-1 production in human synovial fibroblasts by reducing the activity of the activator protein 1. Osteoarthr Cartil 2002;10:100-8.
9. Bordji K, Grillasca J P, Gouza JN, Magdalou J, Schohn H, Keller JM, et al. Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) alpha and gamma and retinoid Z receptor in cartilage. PPAR-gamma activation modulates the effects of interleukin-1 beta on rat chondrocytes. J Biol Chem 2000;275:12243-50.
10. Kobayashi T, Notoya K, Naito T, Unno S, Nakamura A, Martel-Pelletier J, et al. Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the pregression of experimental osteoarthritis in guinea pigs. Arthritis Rheum 2005;52:479-87.
11. Knouff C, Auwerx J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: Lessons from genetics and pharmacology. Endocr Rev 2004;25:899-918.
12. Kellgren JK, Lawrence JS. Radiological assessment of the osteoarthritis. Ann Rheum Dis 1957;16:494-501.
13. Sambrook J, Freitsch EF, Maniatis T. Molecular cloning: A laboratory manual. 2nd ed. NY USA: Cold Spring Harbor Laboratory; 1989.
14. Ogawa S, Urano T, Hosoi T, Miyao M, Hoshino S, Fujita M, et al. Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPAR-gamma expression in osteoblasts. Biochem Biophys Res Commun 1999;260:122-6.
15. Oh EY, Min KM, Chung JH, Min YK, Lee MS, Kim KW, et al. Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor g2 in Korean diabetic and obese subjects. J Clin Endocrinol Metab 2000;85:1801-4.
16. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall D P, et al. Molecular scanning of the human peroxisome proliferator-activated receptor g (hPPARg) gene in diabetic Caucasians: Identification of a Pro12Ala PPARG2 missense mutation. Biochem Biophys Res Commun 1997;241:270-4.
17. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998;41:1343-55.
18. Valdes AM, Van Oene M, Hart DJ, Surdulescu GL, Loughlin J, Doherty M, et al. Reproducible genetic associations between candidate genes and clinical knee osteoarthritis in men and women. Arthritis Rheum 2006;54:533-9.
19. Abel K, Reneland R, Kammerer S, Mh S, Hoyal C, Cantor CR, et al. Genome-wide SNP associations: Identification of susceptibility alleles for osteoarthritis. Autoimmunity Rev 2006;5:258-63.